### ü´Ä Critical Care Medicine: Opioid Toxicity Treatment

#### ‚úÖ True Statements
1. **Opioid toxicity** is characterized by respiratory depression, depressed level of consciousness, and miotic pupils.  
2. **Naloxone**, an opioid antagonist, is the treatment of choice in opioid toxicity.  
3. Naloxone reverses respiratory depression with a therapeutic target of normalizing the respiration rate.  
4. Naloxone has a short half-life, and its antidote effects often subside before the effects of the opioid.  
5. **Sustained-release opioid formulations** and **methadone** have long half-lives, requiring repeated naloxone dosing.  
6. Patients with opioid toxicity should be observed for recurrent respiratory depression.  
7. Patients should also be monitored for signs of **opioid withdrawal**, which requires only supportive care.  
8. Bilevel positive airway pressure is not recommended in the setting of depressed consciousness caused by drug intoxication.  
9. Endotracheal intubation is unnecessary in patients responding to naloxone but is indicated for worsening hypoxemia or inability to protect the airway despite naloxone.  
10. Flumazenil is generally not indicated in patients with polysubstance intoxication because it can precipitate withdrawal seizures in those with long-term benzodiazepine or alcohol use.  
11. Opioids have proportionally greater respiratory depressant effects than benzodiazepines, so the focus should be on reversal of opioid effects.  

#### üí¨ Extra(s)
1. This patient suspected of having opioid toxicity responded to naloxone but developed recurrent respiratory depression, requiring additional naloxone.  
2. In many instances, close monitoring and repeated doses of naloxone can avert the need for intubation.  

#### üìö Reference
Stolbach A, Connors N, Nelson L, et al. ACMT position statement: interpretation of urine opiate and opioid tests. *J Med Toxicol*. 2022;18:176-9. PMID: 34780053 doi:10.1007/s13181-021-00864-1  

#### üè∑Ô∏è Tags
#CriticalCare #Toxicology #OpioidToxicity #Naloxone #RespiratoryDepression  

#### üÜî Question ID
CCMCQ24001  

#### üïí Last Updated
February 2025  

---

#### üìñ Related Text
MKSAP: Critical Care Medicine, Specific Critical Care Topics, Toxicology, Toxicity of Drugs of Abuse

---

### üìò Related Text Derivations

#### ‚úÖ Additional True Statements (from Related Text)
1. An accurate history in cases of drug abuse may be impossible to obtain because of altered mental status, reluctance to disclose drug use, or insufficient knowledge about the composition of the drugs.  
2. **Clinical toxic syndromes** are constellations of symptoms and signs indicative of certain classes of drugs and can provide clues for effective management of overdose.  
3. Care of patients with overdose is primarily supportive, with maintenance of airway patency and ventilation critical in those with decreased mental status.  
4. Patients with drug overdose may need intubation to protect from aspiration or respiratory failure when respiratory drive is impaired.  
5. Suspected opioid overdose warrants an early empiric trial of **naloxone**, which reverses respiratory depression and toxic encephalopathy.  
6. Naloxone should be titrated to adequate respiration rate, not to mental status.  
7. Naloxone has a short half-life, and its antidote effects often subside before the effects of the opioid.  
8. Patients with opioid overdose should be observed for signs of opioid withdrawal, which is not fatal and requires only supportive care.  
9. Continued or recurrent signs of respiratory depression may require repeated dosing of naloxone.  
10. Close monitoring and repeated doses or an intravenous infusion of naloxone can avert the need for intubation.  
11. In suspected benzodiazepine overdose, flumazenil administration can cause life-threatening CNS activation, including seizures, especially in long-term benzodiazepine users.  
12. Flumazenil may be preferable in patients who already have ventilator support, allowing metabolism and elimination of benzodiazepines over time.  
13. In patients who have received sympathomimetic agents such as **cocaine or amphetamines**, **benzodiazepines** are the cornerstone of therapy for agitation.  
14. Œ≤-Blockers should be avoided in sympathomimetic intoxication because blocking Œ≤-adrenergic receptors may leave Œ± receptors unopposed, potentially leading to severe hypertension.  
15. Hallucinogenic agents have no antidote, and management is supportive, including airway, ventilation, and hemodynamic support.  
16. Patients who have ingested hallucinogenic agents may become extremely agitated and combative, requiring restraints or sedation to prevent harm to themselves and others.  

#### üí¨ Extra(s)
1. Difficulty obtaining an accurate drug history is compounded when multiple substances are ingested.  
2. The empiric naloxone trial is recommended before confirmatory testing when opioid overdose is suspected.  
3. An intravenous infusion of naloxone is particularly useful when treating overdoses of long-acting opioids.  
4. The risk of seizures with flumazenil is highest in patients with chronic alcohol use or long-term benzodiazepine therapy.  
5. Sedation of patients who ingest hallucinogens is aimed at preventing injury to both the patient and caregivers.  
---

### üóæ Supplemental HTML Table(s)

<!--Table 1: Toxic Syndromes and Their Manifestations-->

```html
<table>
  <caption>Toxic Syndromes and Their Manifestations</caption>
  <thead>
    <tr>
      <th>Syndrome</th>
      <th>Manifestations</th>
      <th>Representative Drugs</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Sympathomimetic</td>
      <td>
        <ul>
          <li>Tachycardia</li>
          <li>Hypertension</li>
          <li>Diaphoresis</li>
          <li>Agitation</li>
          <li>Seizures</li>
          <li>Mydriasis</li>
        </ul>
      </td>
      <td>
        <ul>
          <li>Cocaine</li>
          <li>Amphetamines</li>
          <li>Ephedrine</li>
          <li>Caffeine</li>
        </ul>
      </td>
    </tr>
    <tr>
      <td>Cholinergic</td>
      <td>
        <ul>
          <li>SLUDGE (Salivation, Lacrimation, increased Urination and Defecation, Gastrointestinal upset, and Emesis)</li>
          <li>Confusion</li>
          <li>Bronchorrhea</li>
          <li>Bradycardia</li>
          <li>Miosis</li>
        </ul>
      </td>
      <td>
        <ul>
          <li>Organophosphates (insecticides, sarin)</li>
          <li>Carbamates</li>
          <li>Physostigmine</li>
          <li>Edrophonium</li>
          <li>Nicotine</li>
        </ul>
      </td>
    </tr>
    <tr>
      <td>Anticholinergic</td>
      <td>
        <ul>
          <li>Hyperthermia</li>
          <li>Dry skin and mucous membranes</li>
          <li>Agitation, delirium</li>
          <li>Tachycardia, tachypnea</li>
          <li>Hypertension</li>
          <li>Mydriasis</li>
        </ul>
      </td>
      <td>
        <ul>
          <li>Antihistamines</li>
          <li>Tricyclic antidepressants</li>
          <li>Anti-Parkinson agents</li>
          <li>Atropine</li>
          <li>Scopolamine</li>
        </ul>
      </td>
    </tr>
    <tr>
      <td>Opioids</td>
      <td>
        <ul>
          <li>Miosis</li>
          <li>Respiratory depression</li>
          <li>Lethargy, confusion</li>
          <li>Hypothermia</li>
          <li>Bradycardia</li>
          <li>Hypotension</li>
        </ul>
      </td>
      <td>
        <ul>
          <li>Morphine, fentanyl, oxycodone, and related drugs</li>
          <li>Heroin</li>
        </ul>
      </td>
    </tr>
  </tbody>
</table>
```

#### ‚úÖ True Statements (from Table: *Toxic Syndromes and Their Manifestations*)
1. **Sympathomimetic** toxidrome manifests with tachycardia, hypertension, diaphoresis, agitation, seizures, and mydriasis.  
2. **Cholinergic** toxidrome manifests with SLUDGE, confusion, bronchorrhea, bradycardia, and miosis.  
3. **Anticholinergic** toxidrome manifests with hyperthermia, dry skin and mucous membranes, agitation or delirium, tachycardia or tachypnea, hypertension, and mydriasis.  
4. **Opioid** toxidrome manifests with miosis, respiratory depression, lethargy or confusion, hypothermia, bradycardia, and hypotension.  

#### üí¨ Optional Extra(s)
1. Representative sympathomimetic drugs include cocaine, amphetamines, ephedrine, and caffeine.  
2. Representative cholinergic agents include organophosphates (insecticides, sarin), carbamates, physostigmine, edrophonium, and nicotine.  
3. Representative anticholinergic agents include antihistamines, tricyclic antidepressants, anti-Parkinson agents, atropine, and scopolamine.  
4. Representative opioids include morphine, fentanyl, oxycodone, related drugs, and heroin.  

---

<!--Table 2: Presentation and Management of Some Drugs of Abuse-->

```html
<table>
  <caption>Presentation and Management of Some Drugs of Abuse</caption>
  <thead>
    <tr>
      <th>Drug Class</th>
      <th>Examples</th>
      <th>Examination Findings</th>
      <th>Antidote</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Opioids</td>
      <td>Heroin, oxycodone, fentanyl analogs</td>
      <td>Bradycardia, hypothermia, hypotension, decreased respiration rate, miosis</td>
      <td>Naloxone</td>
    </tr>
    <tr>
      <td>Benzodiazepines</td>
      <td>Lorazepam</td>
      <td>CNS depression, typically normal vital signs and eye examination</td>
      <td>Flumazenil (not generally recommended; reversal of benzodiazepine effect may lead to seizure)</td>
    </tr>
    <tr>
      <td rowspan="5">Sympathomimetics</td>
      <td>All</td>
      <td>Tachycardia, hypertension, fever, diaphoresis, mydriasis, agitation, seizure, ‚Üë creatine kinase, ‚Üë liver chemistry studies, ‚Üë creatinine</td>
      <td>Benzodiazepines are first line for agitation; avoid Œ≤-blockers for hypertension; haloperidol may worsen hyperthermia</td>
    </tr>
    <tr>
      <td>Cocaine</td>
      <td>Myocardial infarction prominent; 30-minute duration</td>
      <td>‚Äî</td>
    </tr>
    <tr>
      <td>Methamphetamine</td>
      <td>Violent agitation prominent; hyponatremia; 20-hour duration</td>
      <td>‚Äî</td>
    </tr>
    <tr>
      <td>MDMA (‚Äúecstasy‚Äù)</td>
      <td>Hyponatremia, serotonin syndrome</td>
      <td>‚Äî</td>
    </tr>
    <tr>
      <td>Bath salts (‚Äúplant food‚Äù)</td>
      <td>Hallucinations, violent agitation are common; duration up to 48 hours; negative urine drug screen</td>
      <td>‚Äî</td>
    </tr>
    <tr>
      <td rowspan="5">Hallucinogens</td>
      <td>Dextromethorphan</td>
      <td>Tachycardia, hypertension, agitation, coma</td>
      <td>‚Äî</td>
    </tr>
    <tr>
      <td>Lysergic acid diethylamide (LSD)</td>
      <td>Mild tachycardia; hypertension; rare fever and hemodynamic instability</td>
      <td>Benzodiazepines are first line for agitation; haloperidol is second line</td>
    </tr>
    <tr>
      <td>Phencyclidine (PCP)</td>
      <td>Variable mental status: ‚Üë agitation, CNS depression, nystagmus</td>
      <td>‚Äî</td>
    </tr>
    <tr>
      <td>Synthetic cannabinoids (‚ÄúSpice,‚Äù ‚ÄúK-2‚Äù)</td>
      <td>Tachycardia; greater agitation than with marijuana; ‚Üë creatinine; negative urine drug screen</td>
      <td>‚Äî</td>
    </tr>
  </tbody>
  <tfoot>
    <tr>
      <td colspan="4">
        <small>CNS = central nervous system; Cr = creatinine; MDMA = 3,4-methylenedioxymethamphetamine.</small>
      </td>
    </tr>
  </tfoot>
</table>
```

#### ‚úÖ True Statements (from Table: *Presentation and Management of Some Drugs of Abuse*)
1. **Opioid** overdose findings include bradycardia, hypothermia, hypotension, decreased respiration rate, and miosis; the antidote is naloxone.  
2. **Benzodiazepine** overdose presents with central nervous system depression with typically normal vital signs and eye examination; flumazenil is not generally recommended because reversal may lead to seizure.  
3. **Sympathomimetic (all)** exposures produce tachycardia, hypertension, fever, diaphoresis, mydriasis, agitation, seizure, and laboratory increases in creatine kinase, liver chemistry studies, and creatinine; benzodiazepines are first-line therapy for agitation, Œ≤-blockers should be avoided for hypertension, and haloperidol may worsen hyperthermia.  
4. **Cocaine** intoxication has myocardial infarction prominent with approximately 30-minute duration.  
5. **Methamphetamine** intoxication has violent agitation prominent with hyponatremia and approximately 20-hour duration.  
6. **MDMA (ecstasy)** intoxication is associated with hyponatremia and serotonin syndrome.  
7. **Bath salts** intoxication commonly causes hallucinations and violent agitation, may last up to 48 hours, and has a negative urine drug screen.  
8. **Dextromethorphan** intoxication may cause tachycardia, hypertension, agitation, and coma.  
9. **LSD** intoxication causes mild tachycardia and hypertension with rare fever and hemodynamic instability; benzodiazepines are first line for agitation and haloperidol is second line.  
10. **PCP** intoxication causes variable mental status with increased agitation, central nervous system depression, and nystagmus.  
11. **Synthetic cannabinoids** intoxication causes tachycardia, greater agitation than with marijuana, increased creatinine, and a negative urine drug screen.  

#### üí¨ Optional Extra(s)
2. ‚ÄúNot generally recommended‚Äù for flumazenil reflects seizure risk when reversing benzodiazepine effects.  
3. Avoiding Œ≤-blockers in sympathomimetic hypertension prevents unopposed Œ±-adrenergic stimulation; concern for hyperthermia limits haloperidol use.  
4. The brief duration noted for cocaine intoxication is approximately 30 minutes in the table.  
5. Methamphetamine effects are prolonged to about 20 hours in the table.  
7. Bath salts may evade standard urine drug screens despite prolonged symptoms (up to 48 hours).  
11. Synthetic cannabinoids may produce agitation more severe than marijuana exposure and are also associated with a negative standard urine drug screen.  
